

Dibenzocyclooctadiene Lignans from *Schisandra wilsoniana* and Their Anti-HIV-1 ActivitiesGuang-Yu Yang,^{†,‡} Yin-Ke Li,^{†,§} Rui-Rui Wang,[⊥] Xiao-Nian Li,[†] Wei-Lie Xiao,^{*,†} Liu-Meng Yang,[⊥] Jian-Xin Pu,[†] Yong-Tang Zheng,[⊥] and Han-Dong Sun^{*,†}

State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, Yunnan, People's Republic of China, Key Laboratory of Tobacco Chemistry of Yunnan Province, Yunnan Academy of Tobacco Science, Kunming 650106, Yunnan, People's Republic of China, School of Chemistry and Biotechnology, Yunnan Nationalities University, Kunming 650031, Yunnan, People's Republic of China, and Key Laboratory of Animal Models and Human Disease Mechanisms and Laboratory of Molecular Immunopharmacology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, Yunnan, People's Republic of China

Received January 30, 2010

Twelve new dibenzocyclooctadiene lignans, marlignans A–L (1–12), together with 16 known compounds, were isolated from the leaves and stems of *Schisandra wilsoniana*. The structures of 1–12 were elucidated by spectroscopic methods including 1D- and 2D-NMR techniques. Compounds 1–12 were evaluated for their anti-HIV activities, of which compounds 3, 6, 8, and 12 showed modest activities with therapeutic index values of 13.2, 15.6, 17.6, and 16.4, respectively.


The plant family Schisandraceae, consisting of the genera *Schisandra* and *Kadsura*, is important medicinally. Many plants of this family are used commonly in Traditional Chinese Medicine for their diverse beneficial bioactivities.¹ Previous studies have shown that plants of the Schisandraceae are rich sources of dibenzocyclooctadiene lignans, which have been found to exhibit anti-HIV,^{2–4} antitumor,⁵ cytotoxic,^{6,7} antioxidant,^{8,9} and antihepatotoxic^{10,11} effects.

Schisandra wilsoniana A. C. Smith (Schisandraceae) is a climbing plant mainly distributed in Heqing, Dali, and Yulong Prefectures of Yunnan Province in mainland China.^{12,13} In previous work, a number of bioactive compounds, such as highly oxygenated nortriterpenoids, carotene sesquiterpenoids, and lignans, were isolated from this plant.^{13–15} Some of these compounds showed anti-HIV-1 and anti-HBV activities in in vitro test systems. Motivated by a search for new bioactive metabolites from this plant, our group has investigated the chemical constituents of the leaves and stems of *S. wilsoniana*, which led to the isolation and characterization of 12 new dibenzocyclooctadiene lignans, marlignans A–L (1–12), along with 16 known substances. Compounds 1–12 were evaluated for their anti-HIV-1 activities, and the results are described herein.

Results and Discussion

A 70% aqueous acetone extract prepared from the leaves and stems of *S. wilsoniana* was partitioned between EtOAc and H₂O. The EtOAc layer was subjected repeatedly to column chromatography on silica gel, Sephadex LH-20, RP-18, and semipreparative RP-HPLC to afford 12 new lignans, named marlignans A–L (1–12), together with 16 known lignans, which were identified as rubrisandrin A,¹⁶ rubrisandrin B,¹⁶ gomisin J,¹⁷ gomisin N,¹⁸ epigomisin O,¹⁸ gomisin O,¹⁸ gomisin S,¹⁹ schisandrin C,²⁰ (–)-gomisin L₂,²¹ angeloylisogomisin O,²² gomisin N,²³ gomisin T,¹⁹ schizandrin,²⁴ (+)-gomisin K,²⁵ angeloygomisin Q,²⁶ and benzoylgomisin Q.²⁵

Compound 1 was obtained as a yellow gum, and the molecular formula was determined as C₂₁H₂₆O₆ by HRESIMS at *m/z* 397.1629 [M + Na]⁺ (calcd *m/z* 397.1627). Its ¹H and ¹³C NMR spectra showed signals for 26 hydrogens and 21 carbons, respectively,



corresponding to two aromatic rings with two aromatic protons (δ_{H} 7.02 and 6.34), two methylene carbons (δ_{C} 35.9 and 39.6), two methine carbons (δ_{C} 34.3 and 41.7), two methyl groups (δ_{C} 13.0 and 21.9; δ_{H} 0.77, d, *J* = 6.8 Hz; δ_{H} 0.89, d, *J* = 6.8 Hz), three phenolic hydroxy groups (δ_{H} 10.43, 10.61, and 11.16), and three methoxy groups (δ_{C} 60.1, 60.6, and 60.5; δ_{H} 3.84, 3.90, and 3.89), suggesting the presence of a biphenyl moiety.²⁷ UV absorption bands at 210 and 241 nm and ¹H–¹H COSY correlations of H-6/H-7/H-8/H-9, H-7/H-17, and H-8/H-18 (Figure 1), together with the HMBC correlations (Figure 1) of H-11 (δ_{H} 6.34) with C-9 (δ_{C} 35.9), C-10 (δ_{C} 134.7), and C-15 (δ_{C} 119.5) and of H-4 (δ_{H} 7.02) with C-5 (δ_{C} 135.2), C-6 (δ_{C} 39.6), and C-16 (δ_{C} 121.7), implied that 1 is a dibenzocyclooctadiene lignan possessing three phenolic hydroxy groups and three methoxy groups. The ¹H and ¹³C NMR spectra of 1 were found to be similar to those of rubrisandrin A.¹⁶ Analysis of the ¹H and ¹³C NMR data of 1 suggested that the only difference was due to a methoxy group in rubrisandrin A on an aromatic ring being replaced by a hydroxy group in 1. In dibenzocyclooctadiene lignans, the chemical shifts of C-3 and C-12 methoxy groups occur at δ_{C} 55–56, whereas the C-1, C-2, C-13, and C-14 methoxy groups are found at δ_{C} 60–61.^{2,17} The disappearance of the ¹³C NMR signal at δ_{C} 55–56 in 1 suggested that two hydroxy groups are located at C-3 and C-12, which was also supported by HMBC correlations of the hydroxy proton signal at δ_{H} 10.61 with C-2, C-3, and C-4 and the hydroxy proton signal

* To whom correspondence should be addressed. Tel: 86-871-5223251. Fax: 86-871-5216343. E-mail: hdsun@mail.kib.ac.cn; xwl@mail.kib.ac.cn.

[†] Kunming Institute of Botany.

[‡] Yunnan Academy of Tobacco Science.

[§] Yunnan Nationalities University.

[⊥] Kunming Institute of Zoology.




Figure 1. Selected HMBC (→) and ^1H - ^1H COSY (---) correlations of **1**.




Figure 2. Key ROESY correlations of compound **1**.

at δ_{H} 10.44 with C-12. The HMBC correlations of another hydroxy proton signal at δ_{H} 11.16 with C-13, C-14, and C-15 indicated that this hydroxy group is located at C-14. The HMBC correlations of three methoxy groups (δ_{C} 60.1, 60.6, 60.5) with C-1, C-2, and C-13 suggested that these methoxy groups could be positioned at C-1, C-2, and C-13, respectively. In the cyclooctadiene ring, the signals for two methines were assigned to C-7 and C-8 with two benzylic methylenes attributed to C-6 and C-9 and two methyl groups located at C-17 and C-18, respectively, based on the analysis of its ^1H - ^1H COSY and HMBC spectra. Thus, the planar structure of **1** was established.

The CD spectrum of **1** gave a negative Cotton effect at 253 nm and a positive Cotton effect at 220 nm, indicating that **1** has a *S*-biphenyl configuration.²⁷ The ROESY correlations between H-4/CH₃-17, H-11/H-9, and H-11/H-8 in **1** suggested a twist-boat-chair (TBC) conformation for the cyclooctadiene ring²⁸ (Figure 2). The substituent positions and stereochemical assignments in the cyclooctadiene ring of **1** were supported by the ROESY correlations of H-4/H-6 α , H-4/CH₃-17, H-7/H-8, CH₃-17/CH₃-18, H-11/H-9 β , H-8/H-6 β , and H-9 α /CH₃-18. Thus, the structure of **1** was determined as shown, and this compound has been given the trivial name marlignan A.

Compounds **2** and **3** were obtained as yellow gums and showed sodiated molecular ions at m/z 397.1629 and 397.1624 in the HRESIMS (both calcd m/z 397.1627), respectively, corresponding to the same molecular formula, C₂₁H₂₆O₆, for both compounds. The ^1H and ^{13}C NMR spectra of **2** and **3** were very similar to those of **1**. The obvious chemical shift differences resulted from the substituent group variations in the aromatic rings. Analysis of the HSQC, HMBC, and ROESY spectra of **2** and **3** showed that the methoxy groups are located at C-2, C-12, and C-13, and the phenolic hydroxy groups at C-1, C-3, and C-14 for **2**. In turn, methoxy groups could be located at C-2, C-3, and C-12, and the phenolic hydroxy groups at C-1, C-13, and C-14 for **3**. Thus, the structures of **2** and **3** were established, and they have been accorded the trivial name marlignan B and C, respectively.

Compound **4**, obtained as a yellow gum, was assigned the molecular formula C₂₂H₂₈O₇ from its HRESIMS at m/z 427.1730 [$\text{M} + \text{Na}$]⁺ (calcd m/z 427.1733). Its ^{13}C and DEPT NMR spectra showed signals for 22 carbons, corresponding to two aromatic rings with two aromatic protons (δ_{H} 6.71 and 6.52), one methylene (δ_{C} 36.5), one oxygenated methine (δ_{C} 80.9), two methyl groups (δ_{C} 37.8 and 36.9), and four methoxy groups (δ_{C} 60.3, 60.8, 60.7, and 60.9), again suggesting the presence of a biphenyl moiety.²⁷ The

HMBC correlations of H-11 (δ_{H} 6.52) with C-9 (δ_{C} 36.9), C-10 (δ_{C} 137.7), and C-15 (δ_{C} 122.6) and of H-4 (δ_{H} 6.71) with C-5 (δ_{C} 136.5), C-6 (δ_{C} 80.9), and C-16 (δ_{C} 123.7), together with ^1H - ^1H COSY correlations of H-6/H-7/H-8/H-9, H-7/H-17, and H-8/H-18 and UV absorption bands at 210 and 241 nm, implied that **4** is also a dibenzocyclooctadiene lignan. The chemical shifts of the methoxy groups (δ_{C} 60.3, 60.8, 60.7, and 60.9) suggested that these are located at C-1, C-2, C-13, and C-14,¹⁷ which was confirmed by analysis of its HMBC spectrum. In the cyclooctadiene ring, the oxygenated methine carbon was assigned to C-6 on the basis of the HMBC correlation from H-4 (δ_{H} 6.71) to C-6 (δ_{C} 80.9). The CD spectrum of **4** (negative Cotton effect at 252 nm and a positive Cotton effect at 223 nm) indicated that **4** has an *S*-biphenyl configuration.²⁷ The ROESY correlations between H-4/CH₃-17 and H-11/H-7 in **4** suggested a TBC conformation for the cyclooctadiene ring. The configuration of the hydroxy group attached to C-6 was deduced as being β -oriented by the chemical shift (δ_{C} 80.9), which was similar to β -oriented derivatives of the gomisin.²⁵ This was confirmed by the ROESY correlation between H-4/H-6 α and H-6 α /CH₃-18. Thus, the structure of **4** (marlignan D) was established, as shown.

Compounds **5**–**8** (marlignans E–H) were all obtained as yellow gums. By comparison of their IR, UV, ^1H and ^{13}C NMR, and ROESY spectra with those of **4**, compounds **5**–**8** were also assigned as *S*-biphenyl-configured dibenzocyclooctadiene lignans with a twisted boat/chair conformation of the cyclooctadiene ring, a quasi-axial CH₃-17, and a quasi-equatorial CH₃-18. Obvious differences between these compounds resulted from the substituent group at C-6. A β -oriented acetoxy group (δ_{H} 1.80; δ_{C} 169.9 and 21.0) was placed at C-6 for **5**, a β -oriented methoxy group (δ_{H} 3.01; δ_{C} 55.7) for **6**, and a β -oriented benzyloxy group (δ_{H} 7.92, 7.32, 7.39; δ_{C} 165.6, 131.1, 130.1, 128.7, 133.1) for **7**. For compound **8**, C-6 was assigned as a carbonyl group (δ_{C} 201.1). Thus, the structures of **5**–**8** were established, as shown.

Compounds **9** and **10** (marlignans I and J) were both obtained as yellow gums. Comparison of ^1H and ^{13}C NMR spectra of **9** with those of **5** disclosed that the main structural differences between two compounds refer to the substituents in the aromatic rings. Two phenolic hydroxy groups were located at C-3 and C-12 for **5**, whereas two methoxy groups could be located at C-3 and C-12 for **9**. By comparison of the ^1H and ^{13}C NMR spectra of **10** with those of **9**, a difference was evident for the substituent group at C-6; that is, a β -oriented ethoxy group (δ_{H} 0.95, t , $J = 7.0$ Hz, and 3.14–3.23, m ; δ_{C} 15.5, 63.7) could be located at C-6 for **10**. Thus, the structures of **9** and **10** were established, as shown.

Compounds **11** and **12** (marlignans K and L) were obtained as yellow gums, and both were assigned the molecular formula C₂₂H₂₈O₇ by HRESIMS at m/z 427.1735 and 427.1737 [$\text{M} + \text{Na}$]⁺ (both calcd m/z 427.1733). The ^1H and ^{13}C NMR spectra of compound **11** showed signals for 28 protons and 22 carbons, respectively, corresponding to two aromatic rings with two aromatic protons (δ_{H} 7.02, 6.36), two methylene carbons (δ_{C} 39.2, 34.2), one methine carbon (δ_{C} 41.9), one oxygenated quaternary carbon (δ_{C} 73.0), two methyl groups, and four methoxy groups. The HMBC correlations of H-11 (δ_{H} 6.36) with C-9 (δ_{C} 34.2), C-10 (δ_{C} 135.4), and C-15 (δ_{C} 119.3) and of H-4 (δ_{H} 6.36) with C-5 (δ_{C} 134.7), C-6 (δ_{C} 39.2), and C-16 (δ_{C} 121.9), together with ^1H - ^1H COSY correlations of H-9/H-8/H-18 and the UV absorptions at 212 and 240 nm, implied that **11** is a dibenzocyclooctadiene lignan possessing two phenolic hydroxy groups and four methoxy groups. The ^1H and ^{13}C NMR spectra of **11** were very similar to those of gomisin T.¹⁹ The differences resulted from the appearance of a phenolic hydroxy group and the lack of a methoxy group in **11** on one of the aromatic rings, which was supported by the absence of a methoxy group signal when compared with gomisin T. Further analysis of the HMBC spectrum showed that four methoxy groups could be located at C-1, C-2, C-3, and C-13, and two phenolic

Table 1. ^{13}C NMR Data of Compounds **1–6** (δ in ppm)

position	1 ^a	2 ^a	3 ^a	4 ^b	5 ^a	6 ^b
1	151.8 s	146.1 s	147.6 s	152.7 s	152.6 s	151.9 s
2	140.5 s	140.0 s	136.2 s	141.8 s	142.1 s	141.3 s
3	150.3 s	148.2 s	150.2 s	151.7 s	151.2 s	150.5 s
4	112.5 d	115.6 d	107.4 d	116.1 d	116.8 d	116.1 d
5	135.2 s	135.1 s	134.5 s	136.5 s	137.2 s	136.8 s
6	39.6 t	39.3 t	39.7 t	80.9 d	81.4 d	90.1 d
7	34.3 d	34.4 d	34.3 d	37.8 d	38.0 d	38.8 d
8	41.7 d	41.4 d	41.5 d	36.9 d	37.2 d	36.5 d
9	35.9 t	36.2 t	36.3 t	36.5 t	39.2 t	37.9 t
10	134.7 s	134.4 s	132.1 s	137.7 s	134.3 s	137.6 s
11	106.9 d	103.6 d	104.0 d	110.7 d	111.5 d	111.1 d
12	148.7 s	150.7 s	151.3 s	151.6 s	149.2 s	149.6 s
13	139.8 s	138.2 s	134.9 s	139.9 s	139.9 s	139.3 s
14	146.4 s	142.5 s	144.1 s	151.9 s	152.1 s	151.3 s
15	119.5 s	118.6 s	119.5 s	122.6 s	121.8 s	121.7 s
16	121.7 s	122.7 s	118.5 s	123.7 s	123.1 s	123.7 s
17	13.0 q	13.1 q	13.1 q	17.5 q	16.8 q	17.2 q
18	21.9 q	21.9 q	21.9 q	17.5 q	16.8 q	17.4 q
1'				169.9 s	55.7 q	
2'				21.0 q		
OMe-1	60.1 q			60.3 q	60.5 q	60.6 q
OMe-2	60.6 q	60.5 q	60.5 q	60.8 q	60.2 q	60.2 q
OMe-3			55.9 q			
OMe-12		55.9 q	56.0 q			
OMe-13	60.5 q	60.6 q		60.7 q	60.4 q	60.5 q
OMe-14				60.9 q	60.6 q	60.9 q

^a Data were recorded in $\text{C}_5\text{D}_5\text{N}$. ^b Data were recorded in CDCl_3 .

hydroxy groups occurred at C-12 and C-14, respectively. In the cyclooctadiene ring, the signal of a methine group (δ_{C} 41.9 d) was assigned at C-8, for an oxygenated quaternary carbon (δ_{C} 73.0) at C-7, and for two benzylic methylenes (δ_{C} 39.2, 34.2) at C-6 and C-9, by analysis of the 2D NMR spectra of **11**. Two methyl groups, Me-17 (δ_{C} 30.1; δ_{H} 1.39, s) and Me-18 (δ_{C} 16.6; δ_{H} 0.72, d, $J = 8.8$ Hz), were assigned at C-7 and C-8, respectively, by analysis of its HMBC spectrum. Thus, the planar structure of **11** was determined.

The CD spectrum of **11** (positive Cotton effect at 250 nm and a negative Cotton effect at 220 nm) indicated that **11** has an *R*-biphenyl configuration.^{19,24} The ROESY correlations between H-4/H-6 and H-11/CH₃-18 in **11** suggested a TBC conformation for the cyclooctadiene ring. The substituent positions and stereochemical assignments in the cyclooctadiene ring of **11** were supported by the ROESY correlations between the protons H-11/H-9 α , H-9 α /CH₃-18, CH₃-17/CH₃-18, H-4/H-6 β , H-8/H-9 β , and H-6 α /CH₃-17. Thus, the structure of **11** was determined, as shown.

The ^1H and ^{13}C NMR spectra of **12** were very close to those of **11**. The obvious chemical shift differences resulted from the different substituent groups in the aromatic rings. Analysis of the HMBC spectra showed that four methoxy groups could be located at C-1, C-2, C-13, and C-14, with two phenolic hydroxy groups positioned at C-3 and C-12. Thus, the structure of **12** was established, as shown.

Since certain dibenzocyclooctadiene lignans from *Schisandra* genus species exhibit potential anti-HIV activities, the new compounds **1–12** were tested for their potencies in preventing the cytopathic effects of HIV-1 in C8166 cells. Cytotoxicity was measured in parallel with the determination of antiviral activity, using AZT as a positive control (0.0043 $\mu\text{g}/\text{mL}$ and $\text{CC}_{50} > 200$ $\mu\text{g}/\text{mL}$).²⁹ The results are shown in Table 3. Of the substances tested, compounds **3**, **6**, **8**, and **12** showed therapeutic index (TI) values of 13.2, 15.6, 17.6, and 16.4, respectively.

Experimental Section

General Experimental Procedures. Optical rotations were measured with a Horiba SEPA-300 polarimeter. UV spectra were obtained using a Shimadzu UV-2401A spectrophotometer. CD spectra were measured on a JASCO J-810 spectropolarimeter. A Tenor 27 spectrophotometer was used for scanning IR spectrometry. 1D and 2D NMR spectra were

Table 2. ^{13}C NMR Data of Compounds **7–12** (δ in ppm)

position	7 ^a	8 ^a	9 ^b	10 ^b	11 ^a	12 ^a
1	152.8 s	152.8 s	151.4 s	151.3 s	152.5 s	152.4 s
2	139.9 s	142.5 s	142.6 s	142.2 s	140.4 s	140.3 s
3	149.2 s	149.1 s	153.0 s	153.3 s	152.9 s	149.2 s
4	116.6 d	113.4 d	111.4 d	111.1 d	111.4 d	112.4 d
5	136.0 s	135.0 s	134.2 s	135.6 s	132.5 s	136.9 s
6	81.9 d	201.1 s	81.0 d	88.5 d	39.2 t	39.1 t
7	37.5 d	41.4 d	36.8 d	37.2 d	73.0 s	72.2 s
8	38.2 d	45.6 d	37.1 d	38.1 d	41.9 d	41.5 d
9	37.9 t	40.1 t	38.4 t	40.7 t	34.2 t	34.2 t
10	135.8 s	136.7 s	136.3 s	137.2 s	134.4 s	134.9 s
11	111.8 d	111.3 d	106.5 d	106.2 d	112.6 d	115.5 d
12	149.0 s	148.5 s	151.9 s	152.8 s	148.2 s	148.6 s
13	137.6 s	139.8 s	140.4 s	140.1 s	137.9 s	139.7 s
14	152.1 s	151.7 s	150.8 s	150.4 s	148.2 s	152.3 s
15	121.9 s	121.2 s	122.4 s	122.5 s	122.6 s	121.6 s
16	123.0 s	123.0 s	123.2 s	123.6 s	123.7 s	122.5 s
17	13.0 q	15.6 q	16.8 q	16.5 q	30.1 q	29.8 q
18	17.9 q	15.7 q	16.8 q	16.5 q	16.6 q	16.9 q
1'	165.6 s		170.0 s	63.7 t		
2'	131.1 s		21.1 q	15.5 q		
3', 7'	130.1 d					
4', 6'	128.7 d					
5'	133.1 d					
OMe-1	60.4 q	60.6 q	60.0 q	60.3 q	60.7 q	60.5 q
OMe-2	60.2 q	60.8 q	59.7 q	60.9 q	60.8 q	60.7 q
OMe-3			55.7 q	55.8 q	55.7 q	
OMe-12			55.8 q	56.0 q		
OMe-13	60.3 q	60.9 q	60.9 q	60.5 q	61.0 q	60.5 q
OMe-14	60.5 q	60.7 q	60.4 q	60.7 q		60.8 q

^a Data were recorded in $\text{C}_5\text{D}_5\text{N}$. ^b Data were recorded in CDCl_3 .

Table 3. Anti-HIV Activities of Compounds **1–12**

compound	CC_{50} ($\mu\text{g}/\text{mL}$)	EC_{50} ($\mu\text{g}/\text{mL}$)	TI
1	15.8	2.6	6.0
2	43.4	5.1	8.4
3	65.6	5.0	13.2
4	14.2	2.5	5.7
5	13.7	1.6	8.7
6	21.4	1.4	15.6
7	14.2	2.1	6.7
8	46.5	2.6	17.6
9	13.5	2.9	4.6
10	17.2	1.9	9.3
11	14.8	1.9	7.7
12	22.6	1.4	16.4

recorded on a DRX-500 NMR spectrometer with TMS as internal standard. Unless otherwise specified, chemical shifts (δ) are expressed in ppm with reference to the solvent signals. HRESIMS was performed on a VG Autospec-3000 spectrometer. Semipreparative HPLC was performed on a Shimadzu LC-8A preparative liquid chromatograph with Zorbax PrepHT GF (21.2 mm \times 25 cm) or Venusil MP C₁₈ (20 mm \times 25 cm) columns. Column chromatography was performed using silica gel (200–300 mesh, Qing-dao Marine Chemical, Inc., Qingdao, People's Republic of China), Lichroprep RP-18 gel (40–63 μm , Merck, Darmstadt, Germany), and MCI gel (75–150 μm , Mitsubishi Chemical Corporation, Tokyo, Japan). The fractions were monitored by TLC, and spots were visualized by heating silica gel plates sprayed with 5% H_2SO_4 in EtOH.

Plant Material. The leaves and stems of *S. wilsoniana* were collected on Marer Mountain in Dali Prefecture, Yunnan Province, People's Republic of China, in July 2005. The identification of the plant material was verified by Prof. Xi-Wen Li of Kunming Institute of Botany, Chinese Academy of Sciences. A voucher specimen (KIB 05-7-12) has been deposited in the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences.

Extraction and Isolation. The air-dried and powdered leaves and stems of *S. wilsoniana* (8.0 kg) were extracted four times with 70% aqueous Me_2CO (4 \times 10 L) at room temperature and filtered, with the filtrate evaporated under reduced pressure and partitioned with EtOAc (3 \times 4 L). The EtOAc partition (636 g) was applied to silica gel

(200–300 mesh) column chromatography, eluting with a CHCl_3 –MeOH gradient system (20:1, 9:1, 8:2, 7:3, 6:4, 5:5), to give five fractions A–E. The further separation of fraction A (150 g) by silica gel column chromatography, eluted with petroleum ether–acetone (20:1–1:2), yielded mixtures A1–A7. Fraction A1 (35 g) was subjected to silica gel column chromatography using petroleum ether–acetone and semipreparative HPLC (75% MeOH– H_2O , flow rate 12 mL/min) to give **9** (4.2 mg), **10** (7.4 mg), gomisins J (15.8 mg), gomisins N (22.6 mg), angeloylisogomisin O (58.4 mg), and gomisins N (158 mg). Fraction A2 (8.2 g) was subjected to silica gel column chromatography using petroleum ether–acetone and semipreparative HPLC (65% MeOH– H_2O , flow rate 12 mL/min) to give **5** (2.8 mg), **6** (3.9 mg), **7** (1.8 mg), epigomisin O (123 mg), gomisins O (28.5 mg), schisandrin C (19.2 mg), schizandrin (9.26 mg), (+)-gomisins K (12.9 mg), angeloygomisins Q (11.8 mg), and benzoylgomisins Q (23.4 mg). Fraction A3 (6.5 g) was subjected to silica gel column chromatography using petroleum ether–acetone and semipreparative HPLC (60% MeOH– H_2O , flow rate 12 mL/min) to afford **4** (7.5 mg), **8** (2.1 mg), rubrisandrin A (35.4 mg), rubrisandrins B (16.6 mg), gomisins S (11.9 mg), and (–)-gomisins L₂ (24.8 mg). Fraction A4 (4.6 g) was subjected to silica gel column chromatography using petroleum ether–acetone and semipreparative HPLC (55% MeOH– H_2O , flow rate 12 mL/min) to give **1** (13.2 mg), **2** (11.5 mg), **3** (16.2 mg), **11** (16.2 mg) **12** (20.1 mg), and gomisins T (18.2 mg).

Marlignan A (1): yellow gum; $[\alpha]_{\text{D}}^{24} +42.3$ (c 0.21, MeOH); UV (MeOH) λ_{max} (log ϵ) 210 (5.22), 241 (3.28), 326 (0.45) nm; CD (c 0.02, MeOH), nm ($\Delta\epsilon$) 253 (–17.2), 224 (+7.62), 220 (+5.02); IR (KBr) ν_{max} 3450, 2938, 2875, 2830, 1640, 1595, 1489, 1396, 1328, 1278, 1238, 1195, 1130, 1108, 1065, 1007, 982 cm^{-1} ; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) δ 7.02 (1H, s, H-4), 2.63 (1H, dd, $J = 13.4, 7.0$ Hz, H-6 α), 2.67 (1H, d, $J = 13.3$ Hz, H-6 β), 1.82–1.87 (1H, overlapping, H-7), 1.82–1.87 (1H, overlapping, H-8), 2.07 (1H, d, $J = 13.0$ Hz, H-9 α), 2.48 (1H, dd, $J = 9.2, 13.2$ Hz, H-9 β), 6.34 (1H, s, H-11), 0.77 (3H, d, $J = 6.8$ Hz, H-17), 0.89 (3H, d, $J = 6.8$ Hz, H-18), 3.84, 3.89, 3.90 (3H each, s, 3 \times OMe), 10.43, 10.61, 11.16 (1H each, s, 3 \times OH); ^{13}C NMR data, see Table 1; positive ESIMS m/z 397 [M + Na]⁺; HRESIMS m/z 397.1629 [M + Na]⁺ (calcd for $\text{C}_{21}\text{H}_{26}\text{NaO}_6$, 397.1627).

Marlignan B (2): yellow gum; $[\alpha]_{\text{D}}^{24} +38.5$ (c 0.28, MeOH); UV (MeOH) λ_{max} (log ϵ) 210 (5.16), 240 (3.31), 325 (0.29) nm; IR (KBr) ν_{max} 3468, 2941, 2871, 1638, 1585, 1486, 1468, 1398, 1332, 1280, 1235, 1198, 1072, 1015, 988, 959 cm^{-1} ; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) δ 6.96 (1H, s, H-4), 2.51 (1H, overlapping, H-6 α), 2.66 (1H, d, $J = 13.4$ Hz, H-6 β), 1.81 (1H, m, H-7), 1.87 (1H, m, H-8), 2.14 (1H, d, $J = 13.0$ Hz, H-9 α), 2.51 (1H, overlapping, H-9 β), 6.62 (1H, s, H-11), 0.74 (3H, d, $J = 7.0$ Hz, H-17), 0.92 (3H, d, $J = 7.0$ Hz, H-18), 3.84, 3.88, 3.90 (3H each, s, 3 \times OMe), 10.13, 10.46, 11.11 (1H each, s, 3 \times OH); ^{13}C NMR data, see Table 1; positive ESIMS m/z 397 [M + Na]⁺; positive HRESIMS m/z 397.1629 [M + Na]⁺ (calcd for $\text{C}_{21}\text{H}_{26}\text{NaO}_6$, 397.1627).

Marlignan C (3): yellow gum; $[\alpha]_{\text{D}}^{25} +35.8$ (c 0.18, MeOH); UV (MeOH) λ_{max} (log ϵ) 210 (5.33), 240 (3.30), 328 (0.43) nm; IR (KBr) ν_{max} 3448, 2943, 2881, 2815, 1642, 1586, 1482, 1458, 1392, 1325, 1283, 1235, 1198, 1135, 1102, 1068, 1014, 982, 967 cm^{-1} ; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) δ 6.59 (1H, s, H-4), 2.56 (dd, $J = 13.5, 7.0$ Hz, H-6 α), 2.70 (1H, d, $J = 13.5$ Hz, H-6 β), 1.86–1.88 (1H, overlapping, H-7), 1.86–1.88 (1H, overlapping, H-8), 1.86 (1H, d, $J = 13.0$ Hz, H-9 α), 2.52 (1H, dd, $J = 9.2, 13.3$ Hz, H-9 β), 6.50 (1H, s, H-11), 0.77 (3H, d, $J = 6.8$ Hz, H-17), 0.92 (3H, d, $J = 6.8$ Hz, H-18), 3.69, 3.76, 3.80 (3H each, s, 3 \times OMe), 9.87, 10.08, 10.63 (1H each, s, 3 \times OH); ^{13}C NMR data, see Table 1; positive ESIMS m/z 397 [M + Na]⁺; HRESIMS m/z 397.1624 [M + Na]⁺ (calcd for $\text{C}_{21}\text{H}_{26}\text{NaO}_6$ for 397.1627).

Marlignan D (4): yellow gum; $[\alpha]_{\text{D}}^{25} +42.8$ (c 0.28, MeOH); UV (MeOH) λ_{max} (log ϵ) 210 (5.84), 241 (3.52), 326 (0.52), 345 (0.32) nm; CD (c 0.03, MeOH), nm ($\Delta\epsilon$) 252 (–36.5), 247 (–22.8), 223 (+6.2), 215 (+2.22); IR (KBr) ν_{max} 3480, 3452, 2938, 2865, 2822, 1622, 1546, 1471, 1447, 1387, 1323, 1277, 1233, 1187, 1128, 1118, 1065, 1022, 978, 951 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 6.71 (1H, s, H-4), 5.82 (1H, d, $J = 7.6$ Hz, H-6), 1.95 (1H, overlapping, H-7), 2.19 (1H, m, H-8), 1.94 (1H, overlapping, H-9 α), 2.26 (1H, m, H-9 β), 6.52 (1H, s, H-11), 0.78 (3H, d, $J = 6.6$ Hz, H-17), 0.97 (3H, d, $J = 6.7$ Hz, H-18), 3.65, 3.66, 3.87, 3.89 (3H each, s, 4 \times OMe); ^{13}C NMR data, see Table 1; positive ESIMS m/z 427 [M + Na]⁺; HRESIMS m/z [M + Na]⁺ m/z 427.1730 [M + Na]⁺ (calcd for $\text{C}_{22}\text{H}_{28}\text{NaO}_7$, 427.1733).

Marlignan E (5): yellow gum; $[\alpha]_{\text{D}}^{23} +52.0$ (c 0.25, MeOH); UV (MeOH) λ_{max} (log ϵ) 205 (5.22), 242 (4.28), 285 (2.90), 309 (1.18), 360 (1.85) nm; IR (KBr) ν_{max} 3485, 2970, 2946, 1715, 1622, 1565, 1494, 1450, 1424, 1405, 1362, 1268, 1184, 1145, 1124, 1112, 1023, 876 cm^{-1} ; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) δ 7.42 (1H, s, H-4), 5.94 (d, $J = 8.5$ Hz, H-6), 2.04–2.07 (1H, overlapping, H-7), 2.04–2.07 (1H, overlapping, H-8), 2.20 (1H, dd, $J = 16.1, 6.9$ Hz, H-9 α), 2.47 (1H, m, H-9 β), 6.98 (1H, s, H-11), 0.84 (3H, overlapping, H-17), 0.84 (3H, overlapping, H-18), 3.72, 3.88, 3.92, 3.93 (3H each, s, 4 \times OMe), 11.8, 11.68 (1H each, s, 2 \times OH), 1.80 (3H, s, H-2'); ^{13}C NMR data, see Table 1; positive ESIMS m/z 469 [M + Na]⁺; HRESIMS m/z 469.1842 [M + Na]⁺ (calcd for $\text{C}_{24}\text{H}_{30}\text{NaO}_8$, 469.1838).

Marlignan F (6): yellow gum; $[\alpha]_{\text{D}}^{22} +33.2$; UV (MeOH) λ_{max} (log ϵ) 205 (5.64), 245 (3.28), 329 (0.64), 348 (0.48) nm; IR (KBr) ν_{max} 2948, 2932, 2870, 1622, 1575, 1491, 1456, 1412, 1326, 1272, 1150, 1011 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 6.74 (1H, s, H-4), 3.94 (d, $J = 8.5$ Hz, H-6), 1.64 (1H, brs, H-7), 1.96 (1H, m, H-8), 2.00 (1H, dd, $J = 7.9, 15.0$ Hz, H-9 α), 2.39 (1H, m, H-9 β), 6.50 (1H, s, H-11), 0.88 (3H, overlapping, H-17), 0.88 (3H, overlapping, H-18), 3.76, 3.87, 3.88, 3.89 (3H each, s, 4 \times OMe), 3.01 (3H, s, H-1'); ^{13}C NMR data, see Table 1; positive ESIMS m/z 441 [M + Na]⁺; HRESIMS m/z 441.1892 [M + Na]⁺ (calcd for $\text{C}_{24}\text{H}_{30}\text{NaO}_7$, 441.1889).

Marlignan G (7): yellow gum; $[\alpha]_{\text{D}}^{24} +35.2$ (c 0.21, MeOH); UV (MeOH) λ_{max} (log ϵ) 203 (5.22), 243 (4.22), 281 (2.18), 374 (2.42), 395 (1.87) nm; CD (c 0.04, MeOH), nm ($\Delta\epsilon$) 252 (–56.5), 247 (–42.8), 223 (+11.2), 215 (+7.22); IR (KBr) ν_{max} 3456, 2932, 2878, 1726, 1618, 1552, 1524, 1496, 1452, 1415, 1372, 1365, 1338, 1246, 1196, 1175, 1155, 1132, 1105, 1029, 1014 cm^{-1} ; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) δ 7.32 (1H, s, H-4), 6.28 (1H, d, $J = 8.1$ Hz, H-6), 2.09 (1H, m, H-7), 1.89 (1H, m, H-8), 2.23 (1H, m, H-9 α), 2.41 (1H, m, H-9 β), 7.08 (1H, s, H-11), 0.83 (3H, d, $J = 6.8$ Hz, H-17), 0.91 (3H, d, $J = 6.8$ Hz, H-18), 3.72, 3.74, 3.87, 3.89 (3H each, s, 4 \times OMe), 10.63, 10.32 (1H each, s, 2 \times OH), 7.92 (2H, d, $J = 8.3$ Hz, H-3'), 7.92 (2H, d, $J = 8.3$ Hz, H-3', H-7'), 7.32 (2H, m, H-4', H-6'), 7.39 (2H, m, H-4', H-6'); ^{13}C NMR data, see Table 2; positive ESIMS m/z 531 [M + Na]⁺; HRESIMS m/z 531.1999 [M + Na]⁺ (calcd for $\text{C}_{29}\text{H}_{32}\text{NaO}_8$, 531.1995).

Marlignan H (8): yellow gum; $[\alpha]_{\text{D}}^{25} +26.5$ (c 0.28, MeOH); UV (MeOH) λ_{max} (log ϵ) 203 (5.48) 240 (4.15), 280 (2.25), 370 (2.26) nm; CD (c 0.08, MeOH), nm ($\Delta\epsilon$) 252 (–45.8), 230 (+38.6), 212 (–2.17); IR (KBr) ν_{max} 3468, 2936, 2842, 1732, 1680, 1642, 1588, 1485, 1438, 1402, 1325, 1264, 1230, 1192, 1160, 1122, 1038, 1015 cm^{-1} ; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) δ 8.20 (1H, s, H-4), 1.82 (1H, m, H-7), 3.04 (1H, m, H-8), 2.68 (1H, m, H-9 α), 2.38 (1H, dd, $J = 12.4, 11.2$ Hz, H-9 β), 7.05 (1H, s, H-11), 0.81 (3H, d, $J = 6.6$ Hz, H-17), 1.02 (3H, d, $J = 6.5$ Hz, H-18), 3.70, 3.91, 3.93, 4.00 (3H each, s, 4 \times OMe); ^{13}C NMR data, see Table 2; positive ESIMS m/z 425 [M + Na]⁺; HRESIMS m/z [M + Na]⁺ 425.1571 (calcd for $\text{C}_{22}\text{H}_{26}\text{NaO}_7$, 425.1576).

Marlignan I (9): yellow gum; $[\alpha]_{\text{D}}^{23} +38.4$ (c 0.32, MeOH); UV (MeOH) λ_{max} (log ϵ) 206 (5.88), 242 (3.62), 328 (0.61), 346 (0.47) nm; IR (KBr) ν_{max} 2947, 2862, 1721, 1638, 1582, 1471, 1408, 1381, 1285, 1211, 1130, 1102, 1042, 1014, 852 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 6.70 (1H, s, H-4), 5.64 (1H, d, $J = 8.2$ Hz, H-6), 1.85–1.87 (1H, overlapping, H-7), 1.85–1.87 (1H, overlapping, H-8), 2.43 (1H, m, H-9 α), 2.12 (1H, dd, $J = 8.0, 15.2$ Hz, H-9 β), 6.52 (1H, s, H-11), 0.85 (3H, d, $J = 6.8$ Hz, H-17), 0.96 (3H, d, $J = 7.0$ Hz, H-18), 3.75, 3.78, 3.84, 3.86, 3.91, 3.93 (3H each, s, 6 \times OMe); ^{13}C NMR data, see Table 2; positive ESIMS m/z 497 [M + Na]⁺; HRESIMS m/z 497.2154 [M + Na]⁺ (calcd for $\text{C}_{26}\text{H}_{34}\text{NaO}_8$, 497.2151).

Marlignan J (10): yellow gum; $[\alpha]_{\text{D}}^{24} +35.5$ (c 0.16, MeOH); UV (MeOH) λ_{max} (log ϵ) 205 (5.64), 240 (3.60), 329 (0.64), 348 (0.48) nm; CD (c 0.07, MeOH), nm ($\Delta\epsilon$) 249 (–62.4), 240 (–38.5), 220 (–22.6), 210 (+5.4); IR (KBr) ν_{max} 2948, 2932, 2870, 1622, 1575, 1491, 1456, 1412, 1326, 1272, 1011 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) δ 6.74 (1H, s, H-4), 4.06 (1H, d, $J = 8.2$ Hz, H-6), 1.99–2.02 (1H, m, H-7), 1.85–1.88 (1H, m, H-8), 2.56 (1H, dd, $J = 13.6, 8.1$ Hz, H-9 α), 2.23 (1H, d, $J = 13.0$ Hz, H-9 β), 6.34 (1H, s, H-11), 0.76 (3H, d, $J = 6.9$ Hz, H-17), 0.84 (3H, d, $J = 6.7$ Hz, H-18), 3.79, 3.81, 3.82, 3.86, 3.87, 3.90 (3H each, s, 6 \times OMe), 3.14–3.23 (2H, m, H-1'), 0.95 (3H, t, $J = 7.0$ Hz, H-2'); ^{13}C NMR data, see Table 2; positive ESIMS m/z 483 [M + Na]⁺; HRESIMS m/z 483.2356 [M + Na]⁺ (calcd for $\text{C}_{26}\text{H}_{36}\text{NaO}_7$, 483.2359).

Marlignan K (11): yellow gum; $[\alpha]_{\text{D}}^{25} +42.2$ (c 0.18, MeOH); UV (MeOH) λ_{max} (log ϵ) 208 (5.48), 240 (3.22), 325 (0.52), 345 (0.31) nm; CD (c 0.02, MeOH), nm ($\Delta\epsilon$) 250 (+18.6), 240 (+10.2), 222 (+18.6), 222 (–6.8); IR (KBr) ν_{max} 3452, 2938, 2868, 1610, 1562,

1482, 1463, 1395, 1330, 1276, 1186, 1065, 1025, 976, 948 cm^{-1} ; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) δ 7.02 (1H, s, H-4), 2.83 (1H, d, $J = 13.8$ Hz, H-6 α), 3.22 (1H, d, $J = 13.1$ Hz, H-6 β), 2.17 (1H, m, H-8), 2.62 (1H, d, $J = 10.8$ Hz, H-9 α), 2.51 (1H, dd, $J = 14.6, 6.6$ Hz, H-9 β), 6.77 (1H, s, H-11), 1.39 (3H, s, H-17), 0.72 (3H, d, $J = 8.8$ Hz, H-18), 3.70, 3.88, 3.89, 3.90 (3H each, s, 4 \times OMe), 5.01, 10.26, 11.05 (1H each, s, 3 \times OH); ^{13}C NMR data, see Table 2; positive ESIMS m/z 427 $[\text{M} + \text{Na}]^+$; HRESIMS m/z 427.1735 $[\text{M} + \text{Na}]^+$ (calcd for $\text{C}_{22}\text{H}_{28}\text{NaO}_7$, 427.1733).

Marlignan L (12): yellow gum; $[\alpha]_D^{25} +35.2$ (c 0.24, MeOH); UV (MeOH) λ_{max} (log ϵ) 210 (5.06), 239 (3.48), 330 (0.58), 348 (0.27) nm; IR (KBr) ν_{max} 3449, 2942, 2865, 1622, 1541, 1460, 1392, 1326, 1279, 1189, 1061, 1018, 978, 942 cm^{-1} ; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) δ 7.04 (1H, s, H-4), 2.56 (1H, d, $J = 13.8$ Hz, H-6 α), 3.03 (1H, d, $J = 13.1$ Hz, H-6 β), 1.82 (1H, m, H-8), 2.09 (1H, d, $J = 11.1$ Hz, H-9 α), 2.45 (1H, dd, $J = 14.0, 6.4$ Hz, H-9 β), 6.79 (1H, s, H-11), 1.05 (3H, s, H-17), 0.73 (3H, d, $J = 8.4$ Hz, H-18), 3.75, 3.83, 3.85, 3.95 (3H each, s, 4 \times OMe), 5.18, 11.22, 11.40 (1H each, s, 3 \times OH); ^{13}C NMR data, see Table 2; positive ESIMS m/z 427 $[\text{M} + \text{Na}]^+$; HRESIMS m/z 427.1737 $[\text{M} + \text{Na}]^+$ (calcd for $\text{C}_{22}\text{H}_{28}\text{NaO}_7$, 427.1733).

Anti-HIV-1 Assay. The cytotoxicity assay against C8166 cells (CC_{50}) was assessed using the MTT method, and anti-HIV-1 activity was evaluated by the inhibition assay for the cytopathic effects of HIV-1 (EC_{50}).²⁹

Acknowledgment. This project was supported financially by NSFC (No. 30830115 and 20802082), funds from the Chinese Academy of Sciences ("Xibuzhiguang" to W.-L.X. and no. KSCX1-YW-R-24), 973 Program (nos. 2009CB522303, 2009CB522306, and 2009CB940900), the Scientific and Technological Projects of China (2009ZX09501-029), the Young Academic and Technical Leader Rising Foundation of Yunnan Province (2006PY01-47), and the Natural Science Foundation of Yunnan Province (2005XY04 and 2006B0042Q).

Supporting Information Available: ^1H and ^{13}C NMR, HSQC, HMBC COSY, ROESY, and HRESIMS spectra of **1**, ^1H and ^{13}C NMR, HSQC, and HMBC of **2–4**, **9**, and **11**, H and ^{13}C NMR spectra of **5–8**, **10**, and **12**, and CD spectra of **1** and **11**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References and Notes

- (1) *Pharmacopoeia of the People's Republic of China (Part 1)*; Pharmacopoeia Commission of the Ministry of Public Health of the People's Republic of China: Beijing, 1990; pp 454–455.
- (2) Chang, J. B.; Reiner, J.; Xie, J. X. *Chem. Rev.* **2005**, *105*, 4581–4609.
- (3) Chen, D. F.; Zhang, S. X.; Xie, L.; Xie, J. X.; Chen, K.; Kashiwada, Y.; Zhou, B. N.; Wang, P.; Cosentino, L. M.; Lee, K. H. *Bioorg. Med. Chem.* **1997**, *5*, 1715–1723.

- (4) Pu, J. X.; Yang, L. M.; Xiao, W. L.; Li, R. T.; Lei, C.; Gao, X. M.; Huang, S. X.; Sun, H. D. *Phytochemistry* **2008**, *69*, 1266–1272.
- (5) Chen, D. F.; Zhang, S. X.; Kozuka, M.; Sun, Q. Z.; Feng, J.; Wang, Q.; Mukainaka, T.; Nobukuni, Y.; Tokuda, H.; Nishino, H.; Wang, H. K.; Morris-Natschke, S. L.; Lee, K. H. *J. Nat. Prod.* **2002**, *65*, 1242–1245.
- (6) Shen, Y. C.; Lin, Y. C.; Cheng, Y. B.; Chiang, M. Y.; Liou, S. S.; Khalil, A. T. *Phytochemistry* **2009**, *70*, 114–120.
- (7) Pu, J. X.; Li, R. T.; Xiao, W. L.; Gong, N. B.; Huang, S. X.; Lu, Y.; Zheng, Q. T.; Lou, L. G.; Sun, H. D. *Tetrahedron* **2006**, *62*, 6073–6081.
- (8) Choi, Y. W.; Takamatsu, S.; Khan, S. I.; Srinivas, P. V.; Ferreira, D.; Zhao, Y. P.; Khan, I. A. *J. Nat. Prod.* **2006**, *69*, 356–359.
- (9) Chen, N.; Chiu, P. Y.; Ko, K. M. *Biol. Pharm. Bull.* **2008**, *31*, 1387–1391.
- (10) Wu, M. D.; Huang, R. L.; Yangkuo, L. M.; Hung, C. C.; Ong, C. W.; Kuo, Y. H. *Chem. Pharm. Bull.* **2003**, *51*, 1233–1236.
- (11) Huang, X.; Song, F.; Liu, Z.; Liu, S. *Anal. Chim. Acta* **2008**, *615*, 124–135.
- (12) *Flora Yunnanica*; Science Press: Beijing, 2000; Vol. 11, p 16.
- (13) Yang, G. Y.; Xiao, W. L.; Chang, Y.; Wang, R. R.; Pu, J. X.; Gao, X. M.; Lei, C.; Sun, H. D. *Helv. Chim. Acta* **2008**, *91*, 1871–1878.
- (14) Ma, W. H.; Huang, H.; Zhou, P.; Chen, D. F. *J. Nat. Prod.* **2009**, *72*, 676–678.
- (15) Ma, W. H.; Lu, Y.; Huang, H.; Zhou, P.; Chen, D. F. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4958–4962.
- (16) Chen, M.; Kilgore, N.; Lee, K. H.; Chen, D. F. *J. Nat. Prod.* **2006**, *69*, 1697–1701.
- (17) Ikeya, Y.; Taguchi, H.; Yoshioka, I.; Kobayashi, H. *Chem. Pharm. Bull.* **1979**, *27*, 1583–1588.
- (18) Ikeya, Y.; Taguchi, H.; Yoshioka, I.; Kobayashi, H. *Chem. Pharm. Bull.* **1979**, *27*, 2695–2699.
- (19) Ikeya, Y.; Kanatani, H.; Hakozaiki, M.; Taguchi, H.; Mitsuhashi, H. *Chem. Pharm. Bull.* **1988**, *36*, 3974–3979.
- (20) Lu, H.; Liu, G. T. *Chem. Biol. Interact.* **1991**, *78*, 77–84.
- (21) Ikeya, Y.; Taguchi, H.; Yoshioka, I. *Chem. Pharm. Bull.* **1982**, *30*, 132–139.
- (22) Ikeya, Y.; Ookawa, N.; Taguchi, H.; Yoshioka, I. *Chem. Pharm. Bull.* **1982**, *30*, 3202–3206.
- (23) Tan, R.; Li, L. L.; Fang, Q. C. *Planta Med.* **1984**, *55*, 414–417.
- (24) Ikeya, Y.; Taguchi, H.; Yoshioka, I. *Chem. Pharm. Bull.* **1978**, *26*, 328–331.
- (25) Ikeya, Y.; Taguchi, H.; Yoshioka, I. *Chem. Pharm. Bull.* **1980**, *28*, 2422–2427.
- (26) Ikeya, Y.; Taguchi, H.; Yoshioka, I.; Kobayashi, H. *Chem. Pharm. Bull.* **1979**, *27*, 2536–2538.
- (27) Ikeya, Y.; Taguchi, H.; Yoshioka, I.; Kobayashi, H. *Chem. Pharm. Bull.* **1979**, *27*, 1383–1394.
- (28) Liu, J. S.; Li, L. *Phytochemistry* **1993**, *32*, 1293–1296.
- (29) Wang, J. H.; Tam, S. C.; Huang, H.; Ouyang, D. Y.; Wang, Y. Y.; Zheng, Y. T. *Biochem. Biophys. Res. Commun.* **2004**, *317*, 965–971.

NP100067W